PAVmed (NASDAQ:PAVM) Price Target Raised to $19.50 at Ascendiant Capital Markets

PAVmed (NASDAQ:PAVM) had its price target boosted by Ascendiant Capital Markets from $19.00 to $19.50 in a research note released on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

PAVmed Stock Performance

NASDAQ:PAVM opened at $0.66 on Monday. PAVmed has a 52 week low of $0.55 and a 52 week high of $2.43. The firm has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $0.80. The firm has a market cap of $11.20 million, a price-to-earnings ratio of -0.15 and a beta of 1.13.

Hedge Funds Weigh In On PAVmed

An institutional investor recently raised its position in PAVmed stock. First Manhattan CO. LLC. increased its position in PAVmed Inc. (NASDAQ:PAVM) by 16.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 700,000 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. First Manhattan CO. LLC. owned about 6.32% of PAVmed worth $439,000 as of its most recent SEC filing. 19.93% of the stock is currently owned by institutional investors and hedge funds.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.